The International Mesothelioma Program is directed by Dr. David Sugarbaker and based at Brigham and Women’s Hospital in Boston. It is one of the largest mesothelioma programs in the world, and provides over 300 consultations to mesothelioma patients each year. The IMP draws patients from across the US and internationally, and provides mesothelioma patients and their families with free travel and lodgings during treatment.
The program’s vision is to extend the lives of mesothelioma patients, improve the quality of life of mesothelioma patients and their families, and one day deliver a cure for mesothelioma. To achieve this goal, he IMP supports the emotional well-being of patients and families through a holistic approach to care. The IMP supports patients and families through social work, support groups, chaplaincy, and specialized post discharge nursing care. To provide patients with state-of-the-art medical care, the IMP provides trimodality therapy comprised of surgery, chemotherapy and radiation therapy. Multimodality treatments can include heated intraoperative chemotherapy, which was developed for the optimal treatment of microscopic tumors.
The International Mesothelioma Program is also an active contributor to the field of mesothelioma research. IMP researchers have done extensive work with tumor genomics, including sequencing whole tumor genomes. Their efforts have resulted in the identification of multiple potential vulnerabilities that could be used for targeted treatments in the future. The IMP envisions that the laboratory and clinical trials infrastructure they have established will continue to bring promising therapeutic strategies to fruition. The IMP is committed to using its extensive research resources to find a cure for mesothelioma.